Currently, Sven Ante Lundberg occupies the position of President, CEO, CFO & Non-Executive Director at Merus NV.

He is also on the board of Vor Biopharma, Inc. and Q32 Bio, Inc.

Dr. Lundberg previously occupied the position of Chief Scientific Officer for CRISPR Therapeutics AG, Medical Director at Wyeth Corp., Medical Director for Genzyme Corp., Director & Chief Medical Officer at Taligen Therapeutics, Inc., Vice President & Head-Translational Medicine at Alexion Pharmaceuticals, Inc., Principal at Antisoma Research Ltd., Vice President-Clinical Development at Sarossa Capital Ltd. and Principal at Antisoma, Inc.

He received a doctorate from Stanford University School of Medicine, an MBA from The Isenberg School of Management, an MBA from the University of Massachusetts and an undergraduate degree from Massachusetts Institute of Technology.